Last reviewed · How we verify
NCT03880396
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
trial testing hypofractionated Rth with platinol in Squamous Cell Carcinoma of the Head and Neck in 62 participants. Completed in 26 December 2020.
26 December 2020
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 10 March 2019 |
| Primary completion | 26 December 2020 |
| Estimated completion | 26 December 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- hypofractionated Rth with platinol
Conditions studied
- Squamous Cell Carcinoma of the Head and Neck — all drugs for Squamous Cell Carcinoma of the Head and Neck →
Sponsor
Assiut University
Who can join
Adults 18 to 75, any sex, with Squamous Cell Carcinoma of the Head and Neck. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Linking Iron Metabolism, Ferroptosis, and Cancer: New Targets and Prospects for Effective Anticancer Therapeutic Interventions.
Kourti M, Kontoghiorghes GJ. · · 2026 · PMID 42122232 · DOI 10.3390/cancers18091436
Verify or expand the search:
- PubMed search for NCT03880396
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Squamous Cell Carcinoma of the Head and Neck
Currently open trials in the same condition.
- NCT07465276 — Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC · Phase 2 · recruiting
- NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting
- NCT06223568 — Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subject · Phase 2 · recruiting
- NCT05983133 — A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors · Phase 1 · active not recruiting
- NCT05208762 — A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors · Phase 1 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03880396 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 26 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880396.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing